48,868
edits
m (→Work-up of suspected IHC problems: fix ref.) |
(tweak) |
||
Line 1: | Line 1: | ||
'''Quality''', in pathology, has got a lot of attention lately because there have been high profile screw-ups that lead to significant harm.<ref>URL: [http://www.attorneygeneral.jus.gov.on.ca/inquiries/goudge/index.html http://www.attorneygeneral.jus.gov.on.ca/inquiries/goudge/index.html]. Accessed on: 1 March 2011.</ref><ref>Judicial inquiry probes faulty breast cancer tests. CBC website. URL: [http://www.cbc.ca/news/background/cancer/inquiry.html http://www.cbc.ca/news/background/cancer/inquiry.html]. Accessed on: 30 January 2012.</ref> | '''Quality''', in pathology, has got a lot of attention lately because there have been high profile screw-ups that lead to significant harm.<ref>URL: [http://www.attorneygeneral.jus.gov.on.ca/inquiries/goudge/index.html http://www.attorneygeneral.jus.gov.on.ca/inquiries/goudge/index.html]. Accessed on: 1 March 2011.</ref><ref>Judicial inquiry probes faulty breast cancer tests. CBC website. URL: [http://www.cbc.ca/news/background/cancer/inquiry.html http://www.cbc.ca/news/background/cancer/inquiry.html]. Accessed on: 30 January 2012.</ref> | ||
=General= | |||
The keys to ''quality'' are: | The keys to ''quality'' are: | ||
#Understanding the beeds of the stakeholders (surgeons, oncologists, patients, other pathologists, the public at large). | #Understanding the beeds of the stakeholders (surgeons, oncologists, patients, other pathologists, the public at large). | ||
Line 10: | Line 10: | ||
#Continually doing all of the above with the aim of improving outcomes. | #Continually doing all of the above with the aim of improving outcomes. | ||
=Analysis= | |||
===Overview=== | ===Overview=== | ||
Quality issues can be examined in a number of different ways. | Quality issues can be examined in a number of different ways. | ||
Line 107: | Line 107: | ||
*Statistical process control. | *Statistical process control. | ||
=Measures of quality= | |||
Any number of parameters can be used to measure quality. The when, where and how-often something is measured depends on the value-added. | Any number of parameters can be used to measure quality. The when, where and how-often something is measured depends on the value-added. | ||
Line 150: | Line 147: | ||
**Report delivered to appropriate person? | **Report delivered to appropriate person? | ||
=Immunohistochemistry= | |||
{{Main|Immunohistochemistry}} | {{Main|Immunohistochemistry}} | ||
Line 187: | Line 184: | ||
*Problems can arise at any step. | *Problems can arise at any step. | ||
=Other= | |||
==Failure-potential analysis== | |||
Adapted from Ullman:<ref name=ullman>{{cite book |title=The mechanical design process |last= Ullman |first = David G. |authorlink= |coauthors= |year= 1997 |publisher= McGraw-Hill Companies Inc. |location= Toronto|isbn=0-07-065756-4 |page= |pages= |url= |accessdate=}}</ref> | Adapted from Ullman:<ref name=ullman>{{cite book |title=The mechanical design process |last= Ullman |first = David G. |authorlink= |coauthors= |year= 1997 |publisher= McGraw-Hill Companies Inc. |location= Toronto|isbn=0-07-065756-4 |page= |pages= |url= |accessdate=}}</ref> | ||
#Identify potential individual failures. | #Identify potential individual failures. | ||
Line 195: | Line 192: | ||
#Identify the corrective action. | #Identify the corrective action. | ||
==See also | ==Biopsy size== | ||
Very small tissue fragments are associated with a decreased diagnostic yield and an increased diagnostic uncertainty. | |||
=See also= | |||
*[[Critical values]]. | *[[Critical values]]. | ||
*[[CAP checklists]]. | *[[CAP checklists]]. | ||
=References= | |||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Quality]] | [[Category:Quality]] |
edits